CBER Director Peter Marks (Susan Walsh/Pool via AP Images)
June 21, 2024 04:00 PM EDTUpdated June 24, 03:40 PM
Pharma
Cell/Gene Tx
FDA+

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

Lei Lei Wu

News Reporter

Is Sarep­ta spe­cial? Or has the FDA set a new prece­dent for how it ap­proach­es treat­ments for dev­as­tat­ing dis­eases with few op­tions?

On Thurs­day, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

FDA re­jects Dai­ichi Sanky­o's HER3 ADC, a blow to quick ap­proval plans for Mer­ck part­ner­ship

Maze spins its ALS an­ti­sense pro­gram in­to a se­cre­tive new com­pa­ny

Ab­b­Vie buys Third Rock­'s Cel­sius for $250M to ex­pand IBD pipeline

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

A service from the Financial Times